Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: Sub-analysis of the Japan EPA lipid intervention study (JELIS)

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 2, 2012, Pages 194-204

  Sasaki, Jun ^a   Yokoyama, Mitsuhiro ^b   Matsuzaki, Masunori ^c   Saito, Yasushi ^d   Origasa, Hideki ^e   Ishikawa, Yuichi ^f   Oikawa, Shinichi ^g   Itakura, Hiroshige ^h   Hishida, Hitoshi ⁱ   Kita, Toru ^j   Kitabatake, Akira ^k   Nakaya, Noriaki ^l   Sakata, Toshiie ^m   Shimada, Kazuyuki ⁿ   Shirato, Kunio ^o   Matsuzawa, Yuji ^p  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b Hyogo Brain and Heart Center   (Japan)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOYAMA   (Japan)

^f Kakogawa West City Hospital   (Japan)

^g NIPPON MEDICAL SCHOOL   (Japan)

^h Shinagawa East One Medical Clinic   (Japan)

ⁱ FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^k Hiraoka Hospital   (Japan)

^l Nakaya Clinic   (Japan)

^m Hisatsune Hospital   (Japan)

ⁿ JICHI MEDICAL UNIVERSITY   (Japan)

^o Saito Hospital   (Japan)

^p SUMITOMO HOSPITAL   (Japan)

more..

Author keywords

Coronary artery disease; Eicosapentaenoic acid; Non HDL C; Residual risk

Indexed keywords

CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION;

ADULT; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTERVENTION STUDIES; JAPAN; MALE; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84857523124     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.8326     Document Type: Article

References (43)

1. Ballantyne CM: Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol, 1998; 82: 3Q-12Q
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497
3. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb, 2007; 14: 45-50
4. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998; 279: 1615-1622
5. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350: 1495-1504
6. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435
7. Farwell WR, Sesso HD, Buring JE, Gaziano JM: Nonhigh-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction. Am J Cardiol, 2005; 96: 1129-1134
8. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM: Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol, 2006; 98: 1363-1368
9. Tanabe N, Iso H, Okada K, Nakamura Y, Harada A, Ohashi Y, Ando T, Ueshima H: Serum total and non-high-density lipoprotein cholesterol and the risk prediction of cardiovascular events - the JALS-ECC. Circ J, 74: 1346-1356
10. Robinson JG, Wang S, Smith BJ, Jacobson TA: Metaanalysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol, 2009; 53: 316-322
11. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM: Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation, 2008; 117: 3002-3009
12. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004; 110: 227-239
13. Shimano H, Arai H, Harada-Shiba M, Ueshima H, Ohta T, Yamashita S, Gotoda T, Kiyohara Y, Hayashi T, Kobayashi J, Shimamoto K, Bujo H, Ishibashi S, Shirai K, Oikawa S, Saito Y, Yamada N: Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb, 2008; 15: 116-121
14. Kromann N, Green A: Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand, 1980; 208: 401-406
15. Bang HO, Dyerberg J, Sinclair HM: The composition of the Eskimo food in north western Greenland. Am J Clin Nutr, 1980; 33: 2657-2661
16. Dyerberg J, Bang HO, Hjorne N: Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr, 1975; 28: 958-966
17. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet, 1989; 2: 757-761
18. Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB: Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med, 1997; 336: 1046-1053
19. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE: Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA, 2002; 287: 1815-1821
20. Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S: Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation, 2006; 113: 195-202
21. Morris MC, Manson JE, Rosner B, Buring JE, Willett WC, Hennekens CH: Fish consumption and cardiovascular disease in the physicians' health study: a prospective study. Am J Epidemiol, 1995; 142: 166-175
22. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet, 1999; 354: 447-455
23. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098
24. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K: Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis, 2008; 200: 135-140
25. Sugimoto K, Isobe K, Kawakami Y, Yamada N: The relationship between non-HDL cholesterol and other lipid parameters in Japanese subjects. J Atheroscler Thromb, 2005; 12: 107-110
26. Yokoyama M, Origasa H: Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J, 2003; 146: 613-620
27. Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, Rossbacher JC, Moore IK, Regittnig W, Munoz DS, Kim JH, Shulman GI: n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes, 2007; 56: 1034-1041
28. Raetz CR, Garrett TA, Reynolds CM, Shaw WA, Moore JD, Smith DC Jr, Ribeiro AA, Murphy RC, Ulevitch RJ, Fearns C, Reichart D, Glass CK, Benner C, Subramaniam S, Harkewicz R, Bowers-Gentry RC, Buczynski MW, Cooper JA, Deems RA, Dennis EA: Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. J Lipid Res, 2006; 47: 1097-1111
29. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM: Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science, 2002; 297: 240-243
30. MacDonald ML, Singaraja RR, Bissada N, Ruddle P, Watts R, Karasinska JM, Gibson WT, Fievet C, Vance JE, Staels B, Hayden MR: Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. J Lipid Res, 2008; 49: 217-229
31. Sato A, Kawano H, Notsu T, Ohta M, Nakakuki M, Mizuguchi K, Itoh M, Suganami T, Ogawa Y: Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes, 2010; 59: 2495-2504
32. Hirai A, Terano T, Hamazaki T, Sajiki J, Kondo S, Ozawa A, Fujita T, Miyamoto T, Tamura Y, Kumagai A: The effects of the oral administration of fish oil concentrate on the release and the metabolism of [14C]arachidonic acid and [14C]eicosapentaenoic acid by human platelets. Thromb Res, 1982; 28: 285-298
33. Tamura Y, Hirai A, Terano T, Takenaga M, Saitoh H, Tahara K, Yoshida S: Clinical and epidemiological studies of eicosapentaenoic acid (EPA) in Japan. Prog Lipid Res, 1986; 25: 461-466
34. Kawano H, Yano T, Mizuguchi K, Mochizuki H, Saito Y: Changes in aspects such as the collagenous fiber density and foam cell size of atherosclerotic lesions composed of foam cells, smooth muscle cells and fibrous components in rabbits caused by all-cis-5, 8, 11, 14, 17-icosapentaenoic acid. J Atheroscler Thromb, 2002; 9: 170-177
35. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet, 2003; 361: 477-485
36. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN: Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med, 2005; 201: 713-722
37. Zhao Y, Joshi-Barve S, Barve S, Chen LH: Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr, 2004; 23: 71-78
38. Satoh N, Shimatsu A, Kotani K, Sakane N, Yamada K, Suganami T, Kuzuya H, Ogawa Y: Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care, 2007; 30: 144-146
39. Oh da Y, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM: GPR120 is an omega-3 fatty acid receptor mediating potent antiinflammatory and insulin-sensitizing effects. Cell, 2010; 142: 687-698
40. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A: Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endotheliumdependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol, 1999; 33: 633-640
41. Okuda Y, Kawashima K, Sawada T, Tsurumaru K, Asano M, Suzuki S, Soma M, Nakajima T, Yamashita K: Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Biochem Biophys Res Commun, 1997; 232: 487-491
42. Nakamura N, Hamazaki T, Kobayashi M, Ohta M, Okuda K: Effects of eicosapentaenoic acids on remnantlike particles, cholesterol concentrations and plasma fatty acid composition in patients with diabetes mellitus. In Vivo, 1998; 12: 311-314
43. Ando M, Sanaka T, Nihei H: Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol, 1999; 10: 2177-2184